# OnCo record camrelizumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/camrelizumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "camrelizumab" ;
  schema:name "Camrelizumab"@en ;
  schema:description "Camrelizumab is Jiangsu Hengrui's humanised PD-1 antibody, approved in China for oesophageal, liver and lung cancer but not in the US, where its liver cancer combination with rivoceranib drew complete response letters in 2024 and 2025 over manufacturing and inspection issues. Its signature side effect is reactive cutaneous capillary endothelial proliferation, a skin reaction seen in most patients."@en ;
  schema:url <https://onco.cc/drugs/camrelizumab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Camrelizumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q60785565> ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/38870932/> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-PD-1)" ;
  schema:alternateName "AiRuiKa" ;
  onco:approval "China 2019: Classical Hodgkin lymphoma; subsequently HCC, NSCLC, ESCC (second line 2020, first line with chemotherapy 2021), nasopharyngeal" ;
  onco:cancers <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/nasopharyngeal/>, <https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:companies <https://onco.cc/companies/hengrui/> ;
  onco:terms <https://onco.cc/terms/irae/> ;
  onco:trials <https://onco.cc/trials/escort-1st/>, <https://onco.cc/trials/captain-1st/>, <https://onco.cc/trials/nct04639180/>, <https://onco.cc/trials/nct05320692/>, <https://onco.cc/trials/nct05841472/>, <https://onco.cc/trials/nct06361888/>, <https://onco.cc/trials/nct04906993/>, <https://onco.cc/trials/nct04342910/> .